Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose rosuvastatin plus ezetimibe versus high-dose rosuvastatin in acute myocardial infarction after PCI
KCT0005036Phase 4
Key facts
- Status
- Not yet recruiting
- Start
- Jun 2020
- Countries
- 1
- Sponsor
- Hanmi Pharmaceutical
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Conditions
- myocardial infarction (MI)
01
Overview
Phase 4, randomised, open-label trial in myocardial infarction (MI) comparing High-dose rosuvastatin monotherapy with Low-dose rosuvastatin plus ezetimibe (2 arms). Planned start Jun 2020; status: not yet recruiting.
02
Design
2 arms- Study design
- RandomizedOpen-label
High-dose rosuvastatin monotherapy
Patients receive high-dose rosuvastatin alone after PCI for acute myocardial infarction.
Low-dose rosuvastatin plus ezetimibe
Patients receive low-dose rosuvastatin in combination with ezetimibe after PCI for acute myocardial infarction.
03
Who it enrols
Adult patients in Korea with acute myocardial infarction who have undergone percutaneous coronary intervention.
Beyond the preview
Go deeper on KCT0005036.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005036.